1. Pharmacometabonomics and Personalised Medicine, J. R. Everett, R-L. Loo and F. S. Pullen, Annals of Clinical Biochemistry, submitted January 2013
  2. Pharmacometabonomic characterization of xenobiotics and endogenous metabolic phenotypes that account for inter-individual variation in isoniazid-induced toxicological response, K. Cunningham, S. P. Claus, J. C. Lindon, E. Holmes, J. R. Everett, J.K. Nicholson, and M. Coen, Journal of Proteome Research, 11 (9), 4630-4642 (2012), ePub August 9th 2012, DOI: 10.1021/pr300430u. On-line at: http://pubs.acs.org/doi/abs/10.1021/pr300430u?mi=1249e0g&af=R&pageSize=20
  3. Longitudinal pharmacometabonomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy, Jeremy K. Nicholson, Jeremy R. Everett and John C. Lindon, Expert Opinion in Metabolism and Toxicology, 8 (2): 135-9 (2012). ePub Jan 17th 2012, doi:10.1517/17425255.2012.646987. 
  4. The article was accompanied by a PNAS Highlight by Professor I. D. Wilson entitled Drugs, bugs, and personalized medicine: Pharmacometabonomics enters the ring, Proceedings of the National Academy of Sciences (PNAS), 106 (34), 14187 – 14188 (2009). On-line at: http://www.pnas.org/content/106/34/14187
  5. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism T. Andrew Clayton, David Baker, John C. Lindon, Jeremy R. Everett, and Jeremy K. Nicholson, Proceedings of the National Academy of Sciences (PNAS), 106 (34), 14728 – 14733 (2009) and on-line: www.pnas.org/cgi/doi/10.1073/pnas.0904489106.
  6. Applications of Metabonomics in Clinical Pharmaceutical R&D, J.R. Everett, The Handbook of Metabonomics and Metabolomics, (J.C. Lindon, J.K. Nicholson and E. Holmes, eds.), Elsevier, Amsterdam, 279 -287 (2007)
  7. Hepatotoxin-induced hypertyrosinemia and its toxicological significance, T. Andrew Clayton, John C. Lindon, Jeremy R. Everett, Claude Charuel, Gilles Hanton, Jean-Loic Le Net, Jean-Pierre Provost and Jeremy K. Nicholson, Arch. Toxicol, 81 (3), 201-210, (2007). DOI 10.1007/s00204-006-0136-7
  8. An integrated metabonomic approach to describe temporal metabolic disregulation induced in the rat by the model hepatotoxin allyl formate, I K. S. Yap, T. Andrew Clayton, H. Tang, J. R. Everett, G. Hanton, J-P. Provost, J-L. Le Net, C. Charuel, J. C. Lindon, J. K. Nicholson, J. Proteome Research, 5, 2675-2684 (2006). DOI: 10.1021/pr0601584
  9. Pharmaco-metabonomic phenotyping and personalised drug treatment, T. A. Clayton, J.C. Lindon, O. Cloarec, H. Antti, C. Charuel, G. Hanton, J.-P. Provost, J.-L. Le Net, D. Baker, R.J. Walley, J.R. Everett and J.K. Nicholson, Nature, 440 (7087), 1073-1077, (2006). DOI: 10.1038/nature04648. On-line at: http://www.nature.com/nature/journal/v440/n7087/full/nature04648.html
  10. Hepatotoxin-induced hypercreatinaemia and hypercreatinuria: their relationship to one another, to liver damage and to weakened nutritional status, T. A. Clayton, J. C. Lindon, J. R. Everett, C. Charuel, G. Hanton, J-L Le Net, J-P Provost and J. K. Nicholson, Arch. Toxicol., 78, 86-96 (2004). DOI: 10.1007/s00204-003-0515-2
  11. An hypothesis for a mechanism underlying hepatotoxin-induced hypercreatinuria, T. A. Clayton, J. C. Lindon, J. R. Everett, C. Charuel, G. Hanton, J.-L. Le Net, J.-P. Provost, J. K. Nicholson, Arch. Toxicol., 77, 208-217 (2003). DOI: 10.1007/s00204-002-0431-x
  12. Metabonomics: Metabolic Processes Studied by NMR Spectroscopy of Biofluids Combined with Pattern Recognition, J.C. Lindon, J.K. Nicholson E. Holmes and J.R. Everett, Concepts in Magnetic Resonance, 12 (5), 289-320 (2000). DOI: 10.1002/1099-0534(2000)12:5<289::AID-CMR3>3.0.CO;2-W. On-line at: http://onlinelibrary.wiley.com/doi/10.1002/1099-0534(2000)12:5%3C289::AID-CMR3%3E3.0.CO;2-W/abstract